Evidence map›Paper›PMID 33002757›Full record

ReviewJournal of the neurological sciences2020

Transcranial magnetic stimulation, deep brain stimulation, and other forms of neuromodulation for substance use disorders: Review of modalities and implications for treatment.

James J Mahoney, Colleen A Hanlon, Patrick J Marshalek, Ali R Rezai, Lothar Krinke

2 registry-linked trialsOpen access · greenAbstract readReview
In one paragraph

Review in Journal of the neurological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 59 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed, 4 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05694754 naunknown statusnot on this mapstarted 2021, after this paper: background citation

Transcranial Magnetic Stimulation and Its Effects on Mayor Depressive Disorder and Smoking Cessation

TypeinterventionalSponsorDr. Julian Reyes LópezRan2021 to 2023Enrolled20ConditionsMajor Depressive Disorder, Smoking ReductionArmsTheta Burst Transcranial Magnetic Stimulation
NCT06765824 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Transcranial Magnetic Stimulation in the Treatment of Dual Disorders: Study in Patients with Depression and Tobacco Addiction

TypeinterventionalSponsorCardenal Herrera UniversityRan2025 to 2026Enrolled36ConditionsMajor Depression, Tobacco AddictionArmsRepetitive Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 4 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Reward Neurocircuitry Predicts Longitudinal Changes in Alcohol Use Following Trauma Exposure.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

James J MahoneyWest Virginia University School of Medicine, Rockefeller Neuroscience Institute, 33 Medical Center Drive, Morgantown, WV 26505, United States of America; WVU Department of Behavioral Medicine and Psychiatry, 930 Chestnut Ridge Road, Morgantown, WV 26505, United States of America; WVU Department of Neuroscience, 64 Medical Center Drive, Morgantown, WV 26505, United States of America. Electronic address: james.mahoney@hsc.wvu.edu.
Colleen A HanlonWake Forest School of Medicine, Cancer Biology and Center for Substance Use and Addiction, 475 Vine Street, Winston-Salem, NC 27101, United States of America.
Patrick J MarshalekWest Virginia University School of Medicine, Rockefeller Neuroscience Institute, 33 Medical Center Drive, Morgantown, WV 26505, United States of America; WVU Department of Behavioral Medicine and Psychiatry, 930 Chestnut Ridge Road, Morgantown, WV 26505, United States of America; WVU Department of Neuroscience, 64 Medical Center Drive, Morgantown, WV 26505, United States of America.
Ali R RezaiWest Virginia University School of Medicine, Rockefeller Neuroscience Institute, 33 Medical Center Drive, Morgantown, WV 26505, United States of America; WVU Department of Neuroscience, 64 Medical Center Drive, Morgantown, WV 26505, United States of America; WVU Department of Neurosurgery, 64 Medical Center Drive, Morgantown, WV 26505, United States of America.
Lothar KrinkeWest Virginia University School of Medicine, Rockefeller Neuroscience Institute, 33 Medical Center Drive, Morgantown, WV 26505, United States of America; WVU Department of Neuroscience, 64 Medical Center Drive, Morgantown, WV 26505, United States of America; Magstim Inc., 9855 West 78 Street, Suite 12, Eden Prairie, MN 55344, United States of America.
Blanchette Rockefeller Neurosciences Institute · USWake Forest University · USWest Virginia University · USWest Virginia University Hospitals · US

Funding

West Virginia IDEA-CTRU54GM104942 · NIGMS · WEST VIRGINIA UNIVERSITY · PI Sally Lynn Hodder · 2012 to 2026
$81.0M
TREATING ETHANOL WITHDRAWAL WITH LORAZEPAM/NALTREXONEP50AA010761 · NIAAA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Lisa M McTeague · 1996 to 2026
$46.8M
Longitudinal Investigation of TMS as a Tool to Improve Alcohol Treatment OutcomesR01AA027705 · NIAAA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ADDICOTT, MERIDETH A., LAURIENTI, PAUL · 2019 to 2023
$3.4M
Translational approaches to TMS treatment development for smokingR01DA044471 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ADDICOTT, MERIDETH A., BICKEL, WARREN K · 2018 to 2021
$2.5M
Longitudinal study of functional connectivity among cocaine users in treatmentR01DA036617 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HANLON, COLLEEN A · 2014 to 2018
$1.6M
Developing brain stimulation as a treatment for pain in opiate dependent individualsR21DA044503 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BORCKARDT, JEFFREY J, HANLON, COLLEEN A · 2018 to 2019
$411k
NIAAA NIH HHS P50 AA010761NIAAA NIH HHS R01 AA027705NIDA NIH HHS R01 DA036617NIDA NIH HHS R01 DA044471NIDA NIH HHS R21 DA044503NIGMS NIH HHS U54 GM104942
6 · The paper itself

Abstract

Given the high prevalence of individuals diagnosed with substance use disorder, along with the elevated rate of relapse following treatment initiation, investigating novel approaches and new modalities for substance use disorder treatment is of vital importance. One such approach involves neuromodulation which has been used therapeutically for neurological and psychiatric disorders and has demonstrated positive preliminary findings for the treatment of substance use disorder. The following article provides a review of several forms of neuromodulation which warrant consideration as potential treatments for substance use disorder. PubMed, PsycINFO, Ovid MEDLINE, and Web of Science were used to identify published articles and clinicaltrials.gov was used to identify currently ongoing or planned studies. Search criteria for Brain Stimulation included the following terminology: transcranial direct current stimulation, transcranial magnetic stimulation, theta burst stimulation, deep brain stimulation, vagus nerve stimulation, trigeminal nerve stimulation, percutaneous nerve field stimulation, auricular nerve stimulation, and low intensity focused ultrasound. Search criteria for Addiction included the following terminology: addiction, substance use disorder, substance-related disorder, cocaine, methamphetamine, amphetamine, alcohol, nicotine, tobacco, smoking, marijuana, cannabis, heroin, opiates, opioids, and hallucinogens. Results revealed that there are currently several forms of neuromodulation, both invasive and non-invasive, which are being investigated for the treatment of substance use disorder. Preliminary findings have demonstrated the potential of these various neuromodulation techniques in improving substance treatment outcomes by reducing those risk factors (e.g. substance craving) associated with relapse. Specifically, transcranial magnetic stimulation has shown the most promise with several well-designed studies supporting the potential for reducing substance craving. Deep brain stimulation has also shown promise, though lacks well-controlled clinical trials to support its efficacy. Transcranial direct current stimulation has also demonstrated promising results though consistently designed, randomized trials are also needed. There are several other forms of neuromodulation which have not yet been investigated clinically but warrant further investigation given their mechanisms and potential efficacy based on findings from other studied indications. In summary, given promising findings in reducing substance use and craving, neuromodulation may provide a non-pharmacological option as a potential treatment and/or treatment augmentation for substance use disorder. Further research investigating neuromodulation, both alone and in combination with already established substance use disorder treatment (e.g. medication treatment), warrants consideration.

Indexed as

Deep Brain StimulationSubstance-Related DisordersTranscranial Direct Current StimulationVagus Nerve StimulationHumansTranscranial Magnetic StimulationDeep brain stimulationFocused ultrasoundNeuromodulationPercutaneous nerve field stimulationSubstance use disorderTranscranial direct current stimulationTranscranial magnetic stimulationTrigeminal nerve stimulationVagus nerve stimulation

Identifiers

PMID33002757
PMCPMC7702181
OpenAlexW3091232918

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.